InterCure is a medical device company founded in 1994 that focuses on respiratory-based methods for treating cardiovascular and pulmonary diseases. The company's flagship product, RESpeRATE, is the only FDA-cleared device clinically proven to lower high blood pressure without side effects. In addition, they are developing InTone, a non-drug treatment for heart failure that has completed phase 2a efficacy clinical trials and is awaiting regulatory approval.
With a $8.00M post-IPO equity investment from Ark Invest in February 11, 2021, InterCure aims to lead the market in non-drug, side-effect-free treatments for prevalent conditions. The company's patented technology platforms and a distinguished management team, board of directors, and Scientific Advisory Board position them for success in the Biotechnology, Health Care, Health and Wellness, Manufacturing, and Medical Devices industries. Headquartered in Ra'anana, Israel, InterCure is poised for substantial growth and impact in the medical device sector.
